Medtronic (NYSE:MDT) today announced CE mark approval and the first commercial European implants for its OmniaSecure system.
MedPage Today on MSN
Mavacamten poised to expand to pediatric obstructive hypertrophic cardiomyopathy
The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...
Medtronic snagged FDA approval for an expanded indication for its OmniaSecure defibrillation lead. Check out why this tiny ...
5 天on MSN
Are heart failure and atrial fibrillation the same disease? Study reveals shared genetic ...
New research from a multi-institutional team, published in Nature Cardiovascular Research, reveals that heart failure and ...
Bayer wins EU nod to expand Kerendia's use in heart failure, backed by strong phase III data, boosting a key drug driving growth and portfolio momentum.
In stabilized heart attack survivors without heart failure or left ventricular (LV) systolic dysfunction, stopping the ...
心脏是人体最重要的器官之一，心脏的跳动是生命维持的前提。同时，一旦心脏“罢工”，生命也将迅速消逝。心脏骤停就是心脏“罢工”的重要表现，它是指心脏射血功能的突然终止。心脏骤停发生4分钟后就可发生不可逆的损害，10分钟即可能造成脑死亡。值得注意的是，心脏骤停常常伴随着心律失常，什么是心律失常？心脏骤停时的 ...
BMY's Camzyos shows strong late-stage results in adolescent heart disease, boosting hopes for expanded use as cardiovascular ...
The European Medicines Agency has backed expanding Namuscla to address muscle rigidity in children and adolescents with rare ...
EU approves Bayer’s Kerendia for new indication in adult patients with heart failure with LVEF =40%: Berlin Tuesday, March 31, 2026, 14:00 Hrs [IST] Bayer, a global enterprise w ...
The results run counter to ABYSS but align with other data showing beta-blockers shouldn’t continue indefinitely after MI.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果